



1 *Research article*

2
3 **EXERCISE CAPACITY IN YOUTH 3X3 BASKETBALL: A COMPARATIVE**
4 **ANALYSIS BETWEEN U15 AND U17 CATEGORIES**

5
6 **Alexandru Chiorescu^{a,b,*}**

7 ^a*Club Sportiv ACS MADMAX, Iași, România*

8 ^b*Universitatea Alexandru Ioan Cuza, Iași, România*

9 ** Corresponding author ORCID: 0009-0007-1087-0367*

10 *E-mail address: alexandruchiorescu@yahoo.com*

11
12 **Abstract**

13 Analyzing effort parameters in 3x3 basketball is necessary due to game intensity, providing coaches with an accurate
14 perspective on the physical components that require optimization in athlete training. This study compares the heart rate and
15 movement profiles of U17 (n = 10, born 2009) and U15 (n = 10, born 2011) players from the ACS MADMAX Iași club in
16 Romania. The players were monitored with Polar GPS chest straps during two training sessions on October 31, 2025. The
17 analyzed metrics are effort distribution across zones Z1–Z5, individual player variation, and movement efficiency. The U15
18 group showed higher physical stress during training: an average Cardio Load (CL) of 42.1 vs. 17.2, time in Z4+Z5 of 26.1% vs.
19 0.5%, and an average heart rate (HR Avg) of 71.9% vs. 59.4% of maximum heart rate (HR max). The distance-to-Cardio Load
20 ratio (km/CL) was higher in the U17 group (0.081 vs. 0.040 km/unit), showing better movement efficiency. Analyzing these two
21 age groups reveals how physical growth changes a player's response to the same training exercises. The data help identify
22 specific individual needs within each category to optimize game-based conditioning.

23
24 **Keywords:** *3x3 basketball, youth athletes, heart rate monitoring, training intensity zones, athletic periodization.*

25 **1. Introduction**

26 For athletic structures and youth training frameworks to be considered genuinely sustainable, they must
27 achieve a balanced integration of four fundamental dimensions: social impact, environmental preservation,
28 economic viability, and institutional integrity (Yang et al., 2020). The fast growth of 3x3 basketball worldwide,
29 especially after its Tokyo 2020 Olympic debut, has changed how young players develop and compete. Its specific
30 rules, such as the fast pace, 12-second shot clock, and continuous play (Sansone et al., 2023), create intense physical
31 demands that differ significantly from traditional 5x5 basketball. Elite 3x3 games keep players at near-maximal
32 heart rate (HR) responses and cause neuromuscular fatigue (Sansone et al., 2023).

33 In modern sports training management, the accurate quantification and monitoring of training load are
34 essential for optimizing athletic performance and reducing health-related risks. This issue is particularly important in
35 youth sports, where inappropriate workloads may impair development and increase the risk of injury and
36 psychological stress (Bergeron et al., 2015). Additionally, the morphofunctional characteristics of young athletes
37 contribute to substantial inter-individual variability in responses to training stimuli (Clemente et al., 2020). More
38 specifically, the transition from the Under-15 (U15) to the Under-17 (U17) category is associated with rapid bone
39 and muscle growth, cardiovascular development, and metabolic adaptations (Montgomery & Maloney, 2018),
40 further emphasizing the need for individualized workload management.

41 The personal contribution of the author is the direct, synchronized field-monitoring of youth physical output
42 within a real competitive framework. Therefore, the purpose of this study is to compare the physiological and
43 locomotor profiles of U17 and U15 youth 3x3 basketball players. To achieve this, I recorded the players' live cardiac



44 responses across five intensity zones and calculate their distance to load ratios during high-intensity tournament
45 simulations.

47 2. Material and method

48
49 I studied 20 male youth basketball players from the same sports club, ACS MADMAX Iași, Romania. The
50 players were divided into two groups based on their competitive age category: the U17 group (n = 10) and the U15
51 group (n = 10). This study is limited by its small size involving 20 total subjects (n = 10 per group) and its focus on
52 a single session, applying this monitoring protocol across a full competitive season would provide a more
53 comprehensive dataset and allow for stronger generalizations.

54 Both teams followed the same training schedule of four sessions per week. We collected all data on October
55 31, 2025, in the same basketball gymnasium to ensure identical indoor conditions. To avoid the influence of
56 different times of day, the groups played back-to-back: the U17 group started at 11:47 (session duration: 28 min., 10
57 s.), and the U15 group started at 13:31 (session duration: 31 min., 52 s.). Before playing, all participants completed a
58 regular 15 minute warm-up consisting of running, dynamic stretching, and ball-handling drills.

59 The integration of GPS-based monitoring systems and physiological parameters, including heart rate (HR),
60 maximum heart rate (HRmax), and Cardio Load, has become essential in modern sports science. These technologies
61 provide accurate, individualized insights into athletes' internal and external training loads, thereby supporting
62 performance optimization, fatigue management, and injury prevention (Impellizzeri et al., 2019; Peake et al., 2018;
63 Martins et al., 2021)

64 During the games, each player wore a wireless cardio-GPS sensor secured to the chest with an elastic strap
65 (Polar Team Pro). The devices tracked real-time movement and cardiac parameters, transmitting the data to a sports
66 performance analysis platform to generate individual and group reports.



68
69 *Fig. 1- Real-time physiological monitoring of the U17 team*

70 The monitored parameters included session duration, calories consumed (kcal), Cardio Load (CL), average
71 heart rate (HR Avg), maximum heart rate (HR Max), total distance covered (km), and the percentage distribution of
72 time and distance across five cardiac effort zones (Z1–Z5).




Fig. 2- Individual physiological data – L.T.




Fig. 3- Individual physiological data – A.P.



Fig. 4 Individual physiological data – M.R.




Fig. 5 -Individual physiological data – D.A.

Figures 2 and 3 illustrate these individual physiological profiles for the U17 category, while Figures 4 and 5 represent the U15 category, all generated by the Polar Team Pro platform (Polar Electro Kempele, Finland). Each report provides a comprehensive overview of the athlete's workload.

3. Findings

Individual physiological profile – U17/2009 Group

Table 1 presents the individual physiological parameters of players in the U17/2009 Group

Player	No.	Kcal	C.Load	Level	HR Avg%	HR Avg BPM	HR Max%	HR Max BPM	Dist (km)	Z5t%	Z4t%	Z3t%	Z2t%	Z1t%
S.T.	12	158	20	Low	65	129	78	155	1.093	0	0	19	40	18
V.A.	6	127	9	Very low	50	100	65	129	1.167	0	0	0	2	48



Player	No.	Kcal	C.Load	Level	HR Avg%	HR Avg BPM	HR Max%	HR Max BPM	Dist (km)	Z5t%	Z4t%	Z3t%	Z2t%	Z1t%
R.R.	8	166	20	Low	64	127	74	148	1.022	0	0	11	56	18
C.C.	11	138	12	Medium	55	109	64	127	1.074	0	0	0	8	71
P.M.	17	225	26	Very low	65	130	80	159	1.259	0	0	27	50	23
L.T.	15	171	25	Very low	69	138	105	211	1.132	0	3	35	29	6
B.D.	20	215	28	Very low	68	135	81	161	1.122	0	1	28	59	7
A.P.	14	146	11	Very low	51	113	64	140	1.587	0	0	0	5	55
J.S.	20	137	11	Low	55	110	75	150	0.973	0	0	2	10	58
D.S.	18	115	10	-	52	105	89	177	0.768	0	1	0	7	49
MEAN		159.80	17.20		59.40	119.60	77.50	155.70	1.12	0.00	0.50	12.20	26.60	35.30

Table 1. Individual physiological parameters and effort zone distribution – U17/2009 Group (n=10, duration 28:10 min)

Individual physiological profile – U15/2011 Group

Table 2 presents the individual physiological parameters of players in the U15/2011 Group, using the same indicators as in Table 1.

Table 2. Individual physiological parameters and effort zone distribution – U15/2011 Group

Player	No.	Kcal	C.Load	Level	HR Avg%	HR Avg BPM	HR Max%	HR Max BPM	Dist (km)	Z5t%	Z4t%	Z3t%	Z2t%	Z1t%
D.A.	19	422	72	Medium	83	166	96	192	1.645	39	27	13	15	3
L.D.	2	337	67	Medium	82	164	97	193	1.602	21	43	19	13	1
H.I.	5	339	55	Medium	76	152	97	194	1.307	22	16	24	29	9
T.C.	10	195	31	Medium	63	125	94	188	1.465	9	14	5	10	31
C.R.	6	320	60	Medium	81	161	99	197	2.022	27	15	37	11	2
M.R.	9	319	42	Medium	70	154	89	195	2.613	0	23	27	24	18
M.D.	3	270	31	Medium	69	138	82	164	1.345	0	4	39	50	5
D.T.	19	149	22	Very low	69	137	80	159	1.075	0	0	34	29	8
P.S.	16	125	14	Low	58	117	84	167	0.883	0	0	4	37	20
A.I.	17	224	27	Medium	68	135	81	161	1.502	0	1	36	38	16
MEAN		270.00	42.10		71.90	144.90	89.90	181.00	1.55	11.80	14.30	23.80	25.60	11.30

4. Discussions

A comparative analysis of the mean physiological parameters between the two teams is presented in Table 3, highlighting the distinct cardiovascular and metabolic profiles exhibited by each group during training.

Table 3. Comparison of mean physiological parameters – U17/2009 Group vs. U15/2011 Group

Parameter	G2009/U17 (n=10)	G2011/U15 (n=10)	Difference (G2-G1)
Session duration	28:10 min	31:52 min	+3:42
Mean calories (kcal)	159.80	270.00	110.2
Mean Cardio Load	17.20	42.10	24.9



Parameter	G2009/U17 (n=10)	G2011/U15 (n=10)	Difference (G2-G1)
Mean HR Avg %	59.40	71.90	12.5
Mean HR Avg BPM	119.60	144.90	25.3
Mean HR Max %	77.50	89.90	12.4
Mean HR Max BPM	155.70	181.00	25.3
Mean distance (km)	1.12	1.55	0.430
% time Z5 (maximal)	0.00	11.80	11.8
% time Z4 (high)	0.50	14.30	13.8
% time Z3 (medium)	12.20	23.80	11.6
% time Z2 (moderate)	26.60	25.60	-1.0
% time Z1 (light)	35.30	11.30	-24.0

Data from the training session reveals a clear age-based disparity: the younger group (G2011/U15) sustained a much higher physical and cardiovascular load compared to the older G2009/U17 athletes. Although the difference in session duration was minor (+3:42 min for U15), the U15 players registered a 69% higher energy expenditure (270.00 vs. 159.80 kcal) and a mean Cardio Load nearly 2.5 times greater than the U17 group (42.10 vs. 17.20). This massive discrepancy is directly supported by the heart rate metrics, where the U15 group operated at a mean of 71.90% HRmax and reached a peak of 89.90% HRmax, while the U17 group remained in a predominantly submaximal zone (59.40% HRmax mean). The distribution of time across intensity zones clearly explains this polarization: while the U17 athletes completely avoided the maximal zone (Z5) and spent a combined 61.9% of the session in light and moderate brackets (Z1-Z2), the U15 players spent over a quarter of the training volume under high-intensity and maximal thresholds (Z4-Z5), while also covering a greater absolute distance (1.55 km vs. 1.12 km).

From a physiological standpoint, the variations between the U17 and U15 teams are related to biological developmental stages. While the older players showed stable cardiac responses to submaximal workloads due to an age-related improvement in managing their own pacing, the U15 team operated under intense cardiovascular strain. Younger, less mature athletes frequently sustain efforts within peak cardiovascular thresholds (Z5 > 90% HR max) often lacking the pacing efficiency required to regulate internal load during uniform team constraints.

Table 4. Inter-individual variability indicators – U15/2011 Group

Parameter	Mean	Min	Max	Range (Max-Min)	CV% (est.)
Calories (kcal)	270.00	125.00	422.00	297.00	55.0%
Cardio Load	42.10	14.00	72.00	58.00	68.9%
HR Avg %	71.90	58.00	83.00	25.00	17.4%
HR Avg BPM	144.90	117.00	166.00	49.00	16.9%
HR Max %	89.90	80.00	99.00	19.00	10.6%
HR Max BPM	181.00	159.00	197.00	38.00	10.5%
Distance (km)	1.55	0.90	2.60	1.70	54.8%

Table 4 highlights the large individual variations within the U15 team, demonstrating that identical training constraints generated highly unequal physical and metabolic responses. This dispersion is most prominent in the internal workload metrics. Cardio Load varied by 58.00 (CV = 68.9%), separating the least taxed player (14.00 units) from the most physically challenged one (72.00 units), with a parallel 297.00 kcal gap in energy expenditure (CV=55.0%). Mechanical volume also differed significantly (CV= 54.8%), as total distance more than doubled from a minimum of 0.883 km to a maximum of 2.613 km. Meanwhile, relative heart rate parameters remained highly uniform, showing lower variability in both mean (CV = 17.4% HRavg) and peak cardiovascular values (CV= 10.6%



127 HRmax). These indicators demonstrate that while the entire group consistently achieved near-maximal cardiac
128 recruitment, the mechanical work performed and the resulting total internal costs were highly asymmetric.

129 Categorizing this intensity into distinct heart rate zones provides a precise method for monitoring internal
130 load, revealing substantial inter-individual variability across both teams. This wide dispersion reflects the marked
131 individual variations in biological maturation typical around 14 years of age. Within the U15 group alone, individual
132 CL ranged from 14 (P.S.) to 72 (D.A.), while total distance ranged from 0.883 km to 2.613 km. This demonstrates
133 the critical importance of individualized internal load monitoring.

134 This approach is heavily supported by recent acute profiling which indicates that recreational 3×3 basketball
135 structures can elicit similar or even superior physiological stimuli and enjoyment levels compared to traditional
136 high-intensity interval training (HIIT) protocols (Buchheit, M., & Laursen, P.B. 2013). However, while such
137 indicators have been predominantly validated in active young adults with established tactical experience, their direct
138 translation to younger subjects remains a critical area of investigation. The pronounced physiological stress
139 observed in the U15 team is indicated by a substantially higher Cardio Load and an average heart rate of 71.9% of
140 their maximum. This reflects the inherent, high-density nature of half-court play. Official medical tracking and
141 performance tests confirm that the work-to-rest density in 3x3 basketball is twice as high as in traditional 5v5
142 basketball (Montgomery et al., 2018). Adolescent athletes within early developmental stages, such as the U15 group,
143 do not possess a fully developed aerobic capacity required to rapidly clear the metabolic by products and lactic acid
144 accumulated during these phases of continuous, explosive effort. This physiological limitation explains why their
145 heart rates remain effectively "locked" in the upper intensity zones (Z4–Z5) throughout the short training sessions.

146 Therefore, training strategies must be individualized. The U17 team requires targeted intensity progression,
147 shifting more volume into the Z3–Z4 through fast-paced bilateral play (Sansone et al., 2023). Meanwhile, outlier
148 profiles like V.A. and D.S. suggest a need for targeted aerobic conditioning; integrating high-intensity interval
149 training (HIIT) or specific small-sided games can enhance their maximal oxygen uptake (VO₂max) and
150 cardiovascular efficiency, allowing them to effectively tolerate higher competitive demands (Buchheit & Laursen,
151 2013).

152 153 **5. Conclusions**

154 This study highlights differences in how U17 and U15 players respond to 3x3 basketball, showing that
155 integrated cardio-GPS monitoring provides a reliable, objective method for tracking training loads. The U15 group
156 experienced higher cardiovascular stress, spending more time in high-intensity zones (Z3–Z5). The distance to
157 cardio-load ratio indicates that U17 players possess better locomotor efficiency and a more developed movement
158 economy. As a result, youth 3x3 basketball coaching requires continuous, standardized workload tracking rather
159 than a uniform approach. Training plans must be adapted to match each athlete's biological maturity and individual
160 internal effort profile.

161 Furthermore, this investigation underscores that looking only at team averages can be misleading. Coaches
162 must account for the high intra-group dispersion in mechanical volume and metabolic costs, particularly within
163 younger teams where biological maturation rates vary. Practically, field practitioners should implement targeted
164 interventions, such as high-intensity interval training (HIIT) or rule conditioned small-sided games to accelerate
165 aerobic conditioning in outlier profiles. At the same time, training for older athletes should be structured to
166 intentionally push them into higher intensity zones (Z3–Z4) through fast-paced bilateral structures.

167 In conclusion, this study highlights the importance of individualized workload monitoring during short 3x3
168 basketball sessions and provides a clearer understanding of the physical demands experienced by young athletes.
169 Longitudinal monitoring across an entire competitive season could offer deeper insight into how players gradually
170 adapt their pacing strategies, heart rate responses, and movement patterns to the sustained demands of competitive
171 basketball (Stojanović et al., 2018).



6. References

- 178
179
180 Bergeron, M. F., Mountjoy, M., Armstrong, N., Chia, M., Côté, J., Emery, C. A., ... & Malina, R. M. (2015).
181 International Olympic Committee consensus statement on youth athletic development. *British Journal of*
182 *Sports Medicine*, 49(13), 843–851. <https://doi.org/10.1136/bjsports-2015-094962>
183 Buchheit, M., & Laursen, P.B. (2013). High-intensity interval training, solutions to the programming puzzle:
184 Part I: Cardiopulmonary emphasis. *Sports Med.* 43, 313– 338; <https://doi.org/10.1007/s40279-013-0029-x>
185 Clemente, F. M., Ardigò, L. P., Song, W., Lenoir, M. E., Rodrigues, L. P., & Sigmundsson, H. (2020).
186 Children's exercise physiology. *Frontiers in Physiology*, 11, 269.
187 <https://doi.org/10.3389/fphys.2020.00269>
188 Impellizzeri, F. M., Marcora, S. M., & Coutts, A. J. (2019). Internal and external training load: 15 years on.
189 *International Journal of Sports Physiology and Performance*, 14(2), 270–273.
190 <https://doi.org/10.1123/ijsp.2018-0935>
191 Martins, N. R. A., Annaheim, S., Spengler, C. M., & Rossi, R. M. (2021). Fatigue monitoring through
192 wearables: A state-of-the-art review. *Frontiers in Physiology*, 12, 790292.
193 <https://doi.org/10.3389/fphys.2021.790292>
194 Montgomery, P. G., & Maloney, B. D. (2018). 3x3 Basketball Competition: Physical and Physiological
195 Characteristics of Elite Players. *Journal of Physical Fitness, Treatment & Sports*, 5(3), Article 555664:
196 DOI:10.19080/JPFMTS.2018.05.555664
197 Peake, J. M., Kerr, G., & Sullivan, J. P. (2018). A critical review of consumer wearables, mobile
198 applications, and equipment for providing biofeedback, monitoring stress, and sleep in physically active
199 populations. *Frontiers in Physiology*, 9, 743. <https://doi.org/10.3389/fphys.2018.00743>
200 Sansone, P.; Conte, D.; Tessitore, A.; Rampinini, E.; Ferioli, D. (2023). A systematic review on the physical,
201 physiological, perceptual, and technical–tactical demands of official 3 × 3 basketball games. *Int. J. Sports*
202 *Physiol. Perform.* 18(11), 1233-1245; <https://doi.org/10.1123/ijsp.2023-0104>
203 Stojanović, E., Stojiljković, N., Scanlan, A.T. et al.(2018). The Activity Demands and Physiological
204 Responses Encountered During Basketball Match-Play: A Systematic Review. *Sports Med* 48, 111–135.
205 <https://doi.org/10.1007/s40279-017-0794-z>
206 Yang, J.J.; Chuang, Y.C.; Lo, H.W.; Lee, T.I. (2020). A two-stage MCDM model for exploring the
207 influential relationships of sustainable sports tourism criteria in Taichung City. *Int. J. Environ. Res.*
208 *Public Health*, 17(7), 2319; <https://doi.org/10.3390/ijerph17072319>



1 *Review article*

2 3 **OSTEOPENIA AND VIBRATION THERAPY:** 4 **A BRIEF NARRATIVE REVIEW**

5 **Dan-Vasile Spulber^{a*}**

6 ^a *Alexandru Ioan Cuza" University Iași, Faculty of Physical Education and Sports, Str. Toma Cozma, nr. 3, Iași 700554, Romania*

7 ** Corresponding author. Tel.: +40726319530;*

8 *E-mail address: dan.vasile.spulber@gmail.com*

9 **Abstract**

10 The skeleton is a tissue that undergoes constant remodelling throughout one's life. This is necessary to allow the 10
11 skeleton develop during growth, respond to the stresses placed on it, and repair structural damage caused by structural fatigue or
12 11 fracture. 12

13 There are three major phases throughout which bone mass changes during one's life: growth, consolidation, and 13
14 involution. Involutional bone loss starts between the ages of 35 and 40 in both sexes, but in women it is accelerated after the 14
15 menopause begins. 15

16 Osteopenia refers to the reduced bone mineral density below normal values without passing the diagnostic limit for 16
17 osteoporosis. 17

18 Vibration therapy uses mechanical vibrations to contract and relax the muscles. Vibrations pass through the body while
19 18 the patient stands, sits or lies on a machine. Generally, it can take two forms: Whole-Body Vibration (WBV) or Focal
20 Vibration 19 (FV). During vibration, skeletal muscles rapidly contract and relax at a certain chosen frequency, which promotes
21 muscle 20 anabolism and improved stretch reflex through the activation of one's muscle spindles. 21

22 While some studies show that it promotes increases in the bone density, alongside stimulating bone remodelling and 22
23 generally being an innovative exercise alternative that has a potential use in metabolic disease and in situations in which patients
24 23 are unable to perform traditional exercises, the evidence is still mixed or contradictory. 24

25 The purpose of this article is to review the recent literature regarding the use of vibration therapy in treating bone 25
26 metabolic disorders and outline potential avenues for future investigation and clinical implementation.

27
28 **Keywords:** Osteopenia, Vibration therapy, Whole-Body Vibration

29 **1. Introduction**

30 Bone is a living, dynamic tissue that undergoes constant remodelling throughout life. This is necessary to
31 allow the skeleton to increase in size during growth, respond to the physical stresses placed on it, and repair
32 structural damage caused by structural fatigue or fracture. The processes of bone resorption and bone formation are
33 usually closely coupled, but bone formation exceeds resorption during skeletal growth, allowing the skeleton to
34 increase in size and density. Later in life resorption outstrips bone formation, leading to involutional bone loss.

35 Bone mass changes throughout life in three major phases: growth, consolidation, and involution. Up to 90%
36 of the ultimate bone mass is deposited during skeletal growth, which lasts until the closure of the epiphyses. There is
37 then a phase of skeletal consolidation lasting for up to 15 years, when bone mass increases further until the peak
38 mass is achieved in the mid-30s. Involutional bone loss then starts between the ages of 35 and 40 in both sexes, but
39 in women there is an acceleration of bone loss in the decade after the menopause (Fillit et al., 2016, p. 565).

40 Osteopenia, or low bone mass, refers to reduced bone mineral density below normal values without fulfilling
41 the diagnostic threshold for osteoporosis. Bone mineral density is determined by dual-energy x-ray absorptiometry
42 (DXA). According to the World Health Organization, osteopenia corresponds to a T-score between -1.0 and -2.5,



43 while a T-score less than -2.5 indicates osteoporosis. Osteopenia arises from an imbalance between bone resorption
44 and formation, influenced by aging, estrogen deficiency, inadequate calcium and vitamin D intake, cigarette
45 smoking, a sedentary lifestyle, and certain medications such as glucocorticoids (Varacallo et al., 2026).

46 The human skeleton is not a static structure; it a metabolically active tissue in a state of continuous
47 remodelling. This ongoing remodeling serves several essential functions: ensuring skeletal growth, adapting to
48 different types of mechanical load, and repairing microdamage before it progresses to an actual fracture.

49 Under normal circumstances, bone resorption and bone formation are 2 complementary processes. During
50 growth, however, the formation is the main process, allowing the skeleton to expand in both size and mineral
51 density. With advancing age, this balance scales in the opposite direction, and resorption begins to outpace
52 formation which in time leads to bone loss.

53 Skeletal mass evolves across three broad phases. The first, the growth phase, accounts for roughly 90% of the
54 eventual bone mass formation, ending with the epiphyseal closure. A consolidation phase follows, extending up to
55 15 years after this point, during which bone mass continues to rise toward its peak, which is typically reached in the
56 mid-30s for both males and females. After that, involutional loss sets in gradually in both men and women from
57 around the age of 35–40. Women, however, face an additional challenge: the years immediately following
58 menopause are associated with an accelerated phase of bone loss that substantially compounds this age-related
59 decline (Fillit et al., 2016, p. 565).

60 Vibration therapy uses mechanical vibrations to contract and relax the muscle fibers. Vibrations pass through
61 the body while the patient stands, sits or lies on a specific machine. Usually, it can be used in two ways: Whole-
62 Body Vibration (WBV) or Focal Vibration (FV) (Physiopedia, n.d.; Royal Osteoporosis Society, n.d.).

63 During vibration, muscles oscillate rapidly between contraction and relaxation at a certain calculated
64 frequency, which in turn promotes muscle anabolism and eventual improved stretch reflex through the activation of
65 the targeted muscle spindles.

66 While some studies show that it promotes increases in the bone density, alongside stimulating bone
67 remodeling and generally being an innovative exercise alternative that has a potential use in metabolic disease and
68 in situations in which patients are unable to perform traditional exercises (National Library of Medicine, n.d), the
69 evidence is still mixed or contradictory (Harvard Health Publishing, 2011).

70 This narrative review synthesizes findings from 40 different sources containing randomized controlled trials,
71 systematic reviews, meta-analyses, animal/ in vitro studies, and one book chapter examining the effects of vibration
72 therapy on bone health. It must be noted that the literature on axial vibration therapy for osteopenia specifically is
73 still limited, thus, this review extrapolates from the pre-existing adjacent studies: studies on osteoporosis and on
74 WBV more broadly (axial vibration is a mechanistically equivalent delivered through the lower limbs). These
75 extrapolations are mentioned in their given chapters.

76 We address six main questions: (1) What are the general trends and findings across the present literature and
77 the given sources? (2) What can we extrapolate to osteopenia and axial vibration from the literature? (3) What are
78 the main characteristics of the study populations and which are the most vulnerable groups? (4) What mechanisms
79 does vibration therapy act with on the bone? (5) What are the main limitations and scientific gaps in knowledge at
80 this point? (6) What are the clinical implications of these findings for practice and future research?

82 2. Main text

84 1. General trends and findings

85
86 Across the sources reviewed, the general image is mixed. Vibration therapy appears capable of slowing or even
87 vaguely reversing bone density decline specifically at the proximal femur and lumbar spine, but the actual effect
88 varies considerably depending on the chosen vibration protocol, population characteristics, intervention duration,
89 and the measurement tools used.



1.1 BMD outcomes: stabilization more reliable than reversal

The most consistent finding across the given studies, including the meta-analyses and the systematic reviews is that vibration therapy is more effective at maintaining the bone mass density compared to actually increasing it in a notable way.

For example, Yin et al. (2024), in a comprehensive overview of 15 systematic reviews involving thousands of participants, explicitly conclude that WBV should be recommended for maintaining bone mass density (BMD) in postmenopausal women rather than improving it. This is a conclusion with direct clinical relevance for the management of osteopenia, where preventing progression to osteoporosis is the primary goal.

That said, several sources show notable positive BMD changes under specific conditions. Regina Dantas Jales de Oliveira et al. (2022), in the largest meta-analysis in the reviewed corpus (23 RCTs, $n=2,089$), found significant improvements in lumbar spine and trochanter BMD specifically for the protocol combining low frequency (~ 30 Hz) and low magnitude (~ 0.3 g) over a high cumulative dose ($>7,000$ minutes, equivalent to daily 20-minute sessions for approximately one year). Li et al. (2024), in a meta-analysis of 13 RCTs, found significant improvements in both lumbar spine and femoral neck BMD at 6 months, though these effects were not sustained at 12-month follow-up, suggesting either a physiological adaptation plateau or insufficient protocol duration.

Importantly, Sen et al. (2020), one of the few direct RCTs in the osteopenic range (T-score -2.0 to -3.0), found significant BMD gains at the femoral neck ($+5.0\%$, $p=0.003$) and L2–L4 ($+1.3\%$, $p=0.005$) after 6 months, alongside functional and quality-of-life improvements, providing evidence that positive BMD effects are achievable in this population.

1.2 Site-specificity: the axial transmission pattern

A mechanical pattern of site-specificity emerges consistently across the literature. Chen et al. (2026), confirmed that the most responsive skeletal sites are those closest to the vibration source: Ward's triangle, the greater trochanter, femoral neck, and L2–L4; all located in the lower axial chain. Effects diminish when it comes to distal sites and are inconsistent at the lumbar spine in aggregate analyses, though subgroup analyses under optimal conditions show some effects.

This pattern is mechanically predictable: vibration enters the body through the feet and is progressively attenuated as it travels up the skeleton. Chen et al. (2026) quantify this precisely, noting that vibration transmissibility peaks at the ankle (10–40 Hz), knee (10–25 Hz), and hip/spine (10–20 Hz), with transmitted power dropping to as little as 1/1000th of platform output at higher frequencies or distal sites. Qin et al. (2019), studying axial vibration through the foot in a bed-rest disuse model, demonstrated significant protective effects specifically at the calcaneus but not at the femoral neck, further confirming the mentioned pattern.

This site-specificity has direct implications for axial vibration therapy design: targeting the calcaneus, tibia, and proximal femur is mechanically sound, while expecting significant lumbar spine effects from standing-platform protocols requires high cumulative doses and optimal transmission conditions (e.g., semi-flexed knees, which Oliveira et al. (2016) and de Oliveira et al. (2022) identify as superior to extended-knee postures for maintaining transmissibility to the spine).

1.3 Protocol heterogeneity: A field-wide challenge

The biggest challenge across the given literature is the high heterogeneity of vibration protocols used across studies. Frequencies range from 8 to 90 Hz, magnitudes from 0.15 g to 12 g, session durations from 1 minute to 1 hour, session frequencies from twice weekly to daily, and intervention durations from 4 weeks to 22 months. This variability means that aggregating results across studies often produces null or highly uncertain pooled effects that hide the real effects found within specific protocol subgroups.

Fratini et al. (2016) demonstrate this exact problem: when all WBV studies are pooled indiscriminately, the weighted mean difference is near zero. But when studies are grouped by a specific parameter, clear significant effects emerge (e.g. side-alternating platforms (Bemben, 2020) or magnitudes above 3 g). DadeMatthews et al. (2022), in a meta-analysis of 40 RCTs, found that frequency across the 6–90 Hz range was not a significant



144 moderator of BMD outcomes, suggesting that within the clinically used range, frequency alone is insufficient to
145 predict efficacy, and protocol combinations (e.g. platform type x magnitude x frequency x total cumulative dose)
146 determine outcomes.

147 148 149 **1.4 Measurement tool sensitivity** 150

151 A recurring theme is the insensitivity of dual-energy X-ray absorptiometry (DXA), which is the most
152 commonly used measurement tool, to the microstructural bone improvements that vibration therapy intends to
153 produce. Rajapakse et al. (2021), in a double-blind RCT, found significant improvements in tibial stiffness (+1.31%
154 vs -2.55% in placebo, $p=0.01$), trabecular bone volume fraction, and vertebral marrow fat fraction by MRI, yet no
155 significant DXA-measured BMD differences between the groups. Bilek et al. (2024) similarly found significant per-
156 protocol benefits using CT-based biomechanical computed tomography (BCT) that were absent on the DXA
157 evaluations. Both studies explicitly attribute this to DXA's inability to detect microstructural changes that are
158 clinically significant for bone strength.

159 This measurement issue has important implications for the interpretation of the literature: The many studies
160 reporting null DXA results for vibration therapy may be underestimating the effects of vibration therapy rather than
161 accurately characterising the biological effects of the intervention. More sensitive imaging modalities (pQCT, HR-
162 pQCT, BCT, MRI-based stiffness) and biochemical markers are needed for a detailed picture.

163 164 **1.5 Secondary benefits: consistent and clinically meaningful** 165

166 Even in studies where BMD effects are equivocal or absent, improvements in musculoskeletal function,
167 balance, and fall-related outcomes are reported with notable consistency. This is clinically significant because, for
168 osteopenic patients, fall prevention is at least as important as BMD improvement. Falls are the proximate cause of
169 over 90% of hip fractures (Beck et al., 2022, Ma et al., 2016).

170 Dutra et al. (2016), in 122 osteopenic postmenopausal women over 12 months, found significant
171 improvements in hip flexor strength (+36.7%), back extensor strength (+36.5%), grip strength, arm curl test,
172 flexibility, and Timed Up and Go (TUG) mobility while using low-intensity vibration (<1 g) alone. Guedes De
173 Aguiar et al. (2023), reviewing 8 RCTs with 1,095 participants, found consistent improvements in muscle strength,
174 jump performance, balance, and chair rise performance. Luo et al. (2017), despite finding null BMD results,
175 reported significant improvement in maximal isometric knee extensor strength. Sen et al. (2020) found significant
176 TUG improvements, quality-of-life gains, and a significant reduction in depressive symptoms.

177 Another element characteristic for vibration therapy would be the pain-reduction potential; Li et al. (2024)
178 found a significant reduction in pain scores in osteoporotic patients. This may be particularly relevant for osteopenic
179 patients with early vertebral loading pain.

180 181 **2. Extrapolation from adjacent literature** 182

183 **2.1 From osteoporosis to osteopenia** 184

185 The majority of the clinical literature addresses osteoporosis ($T\text{-score} \leq -2.5$) rather than osteopenia ($T\text{-score}$
186 -1.0 to -2.5). Direct osteopenia-specific evidence comes from a subset of sources: Kienberger et al. (2022), Dutra et
187 al. (2016), He et al. (2022), Bilek et al. (2024), Rajapakse et al. (2021), parts of Myint Swe et al. (2016) (specifically
188 the Slatkovska and Stolzenberg sub-studies), parts of Oliveira et al. (2016), Tan et al. (2016) (which included 92
189 participants with osteopenia), and Sen et al. (2020), (with $T\text{-scores}$ spanning the osteopenic-osteoporotic boundary).

190 Extrapolation from osteoporosis to osteopenia can be made given several clinical reasons. First, osteopenia
191 and osteoporosis represent points on a continuum of the same pathological process which is accelerated net bone
192 resorption over bone formation, thus interventions that modify this balance are applicable across the full spectrum.
193 Second, the underlying mechanisms (osteoblast-osteoclast coupling, OPG/RANKL signaling, mechanotransduction)
194 are the same, regardless of disease severity. Third, evidence suggest that the response to vibration therapy may



195 actually be greater in osteopenic than in healthy bone: Fratini et al. (2016) find that the skeleton's sensitivity to
196 WBV is inversely related to baseline BMD, and Steppe et al. (2020) show that in the animal models, the OVX-
197 induced osteoporotic bone shows greater responsiveness to LMHFV than healthy bone.

198 Marini et al. (2021), in a systematic review focused on combined physical and pharmacological treatment in
199 osteopenia and osteoporosis, found that only one eligible RCT existed in the literature which is an illustration of how
200 understudied the osteopenia-specific combination therapy space is, and of why extrapolation from the broader
201 osteoporosis literature is currently necessary.

203 2.2 From Whole-Body Vibration to Axial Vibration

204
205 All WBV platform studies reviewed are functionally axial vibration studies in terms of the primary
206 transmission pathway: oscillations enter through the feet and travel upward through the lower limbs to the pelvis and
207 spine. Fratini et al. (2016) specifically notes that vibration delivered through the lower limbs cannot reach the upper
208 body with sufficient intensity to produce meaningful effects there, confirming that WBV is a lower-limb and axial-
209 skeleton therapy.

210 The most directly analogous studies for axial vibration therapy are those using low-magnitude, low-
211 frequency (≤ 40 Hz) standing-platform protocols with foot contact as the entry point (Rajapakse et al., 2021; de
212 Oliveira et al.(2022); Qin et al., (2019); Tan et al., (2016), and the Bilek et al. (2024) study of the OsteoBoost
213 wearable belt; the latter being the only study in the current set to apply targeted vibration directly to the lumbar
214 spine and hips rather than through the feet.

215 The OsteoBoost findings are important for bridging WBV platform evidence to direct axial vibration. In a
216 12-month RCT of 126 osteopenic postmenopausal women, Bilek et al. (2024) found that adherent users (≥ 3
217 sessions/week) experienced 83% less vertebral strength decline and significant preservation of vertebral volumetric
218 BMD compared to sham controls with compliance being the dominant variable. Akbar et al. (2025) confirm that
219 OsteoBoost is now FDA-cleared specifically for osteopenia (T-score -1.0 to -2.49) of the lumbar vertebrae or total
220 hip, delivered at 20–40 Hz with low amplitude. Bilek et al. (2025) additionally report 82% adherence in a real-world
221 home-use context with high usability scores, addressing the practical feasibility concern that has historically limited
222 WBV adoption.

224 3. Demographics, vulnerable populations, and incidence

225 3.1 Overview of study populations

226
227
228 Table 1. The demographic characteristics in the key studies reviewed

Study (Year)	n	Age range	% Female	Primary condition
Singh & Varma (2023)	9 trials reviewed	55–84 yrs	~100%	Postmenopausal osteoporosis + geriatric age
Kienberger et al. (2022)	65	56–63 yrs	100%	Osteopenia (T-score -1.0 to -2.5)
Rajapakse et al. (2021)	80	45–65 yrs	100%	Osteopenia / low bone mass
Dutra et al. (2016)	122	≥ 55 yrs (~63 mean)	100%	Osteopenia (specifically recruited)
He et al. (2022)	67	55–90 yrs (~72–73 mean)	85%	Osteopenia post-TKA
Bilek et al. (2024)	126	~61 yrs mean	100%	Osteopenia (T-score -1.0 to -2.5)
de Oliveira et al. (2022)	2,089 (23 RCTs)	53–82 yrs	100%	Postmenopausal (mixed T-scores)



Study (Year)	n	Age range	% Female	Primary condition
Massini et al. (2025)	202 (7 RCTs)	55–93 yrs	94%	Older adults at fracture risk
DadeMatthews et al. (2022)	~2,000+ (40 RCTs)	7–82 yrs	Predominantly female	Mixed: healthy, postmenopausal, chronic conditions
Zhang et al. (2022)	8,502 (97 RCTs)	Middle-aged to elderly	86%	Osteoporosis / osteopenia (mixed)
Sen et al. (2020)	49 completers	40–65 yrs (~54 mean)	100%	Osteopenia to mild osteoporosis (T-score –2.0 to –3.0)
Ebid et al. (2021)	95	~51 yrs mean	0%	Osteopenia / osteoporosis (male cohort)
Qin et al. (2019)	29	25–48 yrs	41%	Disuse/bed-rest osteopenia (healthy baseline)
Tan et al. (2016)	114	45–≥65 yrs	56%	Osteopenia (n=92) + osteoporosis (n=22)

3.2 Most vulnerable population: postmenopausal women

Across all the sources reviewed, postmenopausal women consistently emerge as both the most studied and most clinically vulnerable population. The biological basis is clear: estrogen withdrawal at menopause accelerates bone resorption by disinhibiting osteoclast activity, leading to bone loss rates of 3–5% per year in the initial postmenopausal years (Singh & Varma, 2023). Tomašević-Todorović et al. (2024) note that osteoporotic vertebral fractures affect approximately 1 in 3 women over 50, compared to 1 in 5 men, establishing the gender disparity in fracture risk.

Within the postmenopausal population, a critical age threshold is identified at 65 years. Marín-Cascales et al. (2018) find that significant femoral neck BMD improvements from WBV are specific to women under 65, with no significant effect in the older subgroup. Tan et al. (2016) similarly find that osteogenic responses to WBV diminish in the ≥65 age group. This suggests that the optimal intervention window for vibration therapy in postmenopausal women is the 50–65 year range coinciding with the highest bone loss rate and greatest potential for intervention to change the trajectory.

3.3 Men: underrepresented but responsive

Men are generally underrepresented in the literature. Zhang et al. (2022), in a network meta-analysis of 97 RCTs with 8,502 participants, counted only 1,174 men versus 7,328 women. Myint Swe et al. (2016) explicitly state that evidence for WBV benefits in elderly men remains insufficient. Chen et al. (2026) note that only 4% of participants across their 14 included RCTs were male.

The notable exception is Ebid et al. (2021), which studied an all-male cohort of 95 men (mean age ~51 years) with osteopenia or osteoporosis. Combined PEMF and exercise (including WBV at 30–40 Hz) produced significant increases in lumbar spine and total hip BMD at 12 weeks, with effects sustained at 6-month follow-up, demonstrating that the pathophysiology and therapeutic response in men are comparable, even if the epidemiological burden is lower. Men with secondary osteoporosis risk factors like hypogonadism, prolonged corticosteroid use or low activity levels) represent a rarely researched group.

3.4 Younger and mixed-sex populations

Qin et al. (2019), studying disuse-induced osteopenia in a bed-rest model with 29 volunteers aged 25–48 (41% female), demonstrate that axial vibration through the foot significantly halves the rate of calcaneus BMD loss



262 compared to controls in a population without age-related osteopenia. This is relevant because it isolates the
263 mechanical effect of vibration from the hormonal side present in postmenopause, suggesting that the osteogenic
264 mechanism is broadly applicable across age and sex. Flores (2018), studying 51 premenopausal women aged 18–26,
265 found significant trochanter BMD increases after just 4 weeks of WBV, establishing that vibration can modulate
266 bone even before peak bone mass is reached with implications for primary prevention guidelines.

267 **3.5 Risk factors and incidence**

268 Tomašević-Todorović et al. (2024) provide a detailed enumeration of osteopenia and osteoporosis risk factors
269 relevant to understanding the target population for vibration therapy:

- 270 • Non-modifiable: age ≥ 50 , female sex, Caucasian or Asian ethnicity, genetic predisposition, and slender
271 physique
- 272 • Hormonal: estrogen deficiency (menopause, surgical oophorectomy), early menopause (<45 years),
273 androgen deficiency in men
- 274 • Lifestyle: sedentary lifestyle, smoking, excess alcohol consumption, low calcium and vitamin D intake
- 275 • Medical: prolonged corticosteroid use, rheumatoid arthritis, hyperthyroidism, malabsorption syndromes,
276 and chronic immobilization

277 Chłystek et al. (2018) note that physical inactivity is among the most modifiable and prevalent risk factors,
278 which is why vibration therapy (which mimics the skeletal loading effects of weight exercise without requiring high
279 amounts of physical effort) is attractive for elderly or mobility-limited patients who cannot engage in conventional
280 exercise programs.

281 **4. Mechanisms of action**

282 Understanding how vibration therapy affects bone at the cellular and molecular level is essential for
283 interpreting clinical findings and creating detailed guidelines. The literature reviewed provides converging evidence
284 for several interacting mechanisms.

285 **4.1 Mechanotransduction and osteocyte signaling**

286 Bone is a mechanosensitive tissue that adapts its mass and architecture in response to mechanical loading.
287 Osteocytes the main and the most abundant cells are the primary mechanosensors. They detect shear stress and
288 transduce mechanical signals into biochemical responses that coordinate osteoblast and osteoclast activity (Olçum
289 et al., 2016, Steppe et al., 2020).

290 Steppe et al. (2020) review 51 studies of LMHFV(Low-Magnitude High-Frequency Vibration) effects on
291 bone cells and confirm that vibration at low magnitudes (<1 g) and frequencies of 20–90 Hz consistently promotes
292 osteogenesis and suppresses bone resorption at the cellular level. Key osteocyte responses include: downregulation
293 of sclerostin (SOST), a potent inhibitor of the Wnt/ β -catenin bone formation pathway, increased gap junctional
294 communication between osteocytes and altered secretory profiles that influence neighbouring osteoblasts and
295 osteoclasts.

302 **4.2 Osteoblast activation and bone formation**

303 Vibration at 30–60 Hz and 0.25–0.5 g increases osteoblast proliferation, matrix mineralization, and
304 upregulates bone-formation markers including alkaline phosphatase (ALP), osteocalcin (OCN), Runx2, bone
305 morphogenetic protein (BMP), Osterix, collagen type I, and OPG (Steppe et al., 2020). He et al. (2022) confirm this
306 in a clinical context, finding significant increases in the bone formation markers PINP and osteocalcin in osteopenic
307 patients receiving WBV following knee arthroplasty.

308 Runge et al. (2018), in a rat model, identified prostaglandin E2 (PGE2) elevation at a +74% in the highest
309 vibration group as a key biochemical mediator of vibration-induced bone anabolism, implicating the COX-2
310 pathway. This provides a distinct mechanistic route from the usual osteocyte-sclerostin pathway and suggests that



vibration instead engages in multiple parallel anabolic mechanisms.

4.3 Osteoclast suppression and bone resorption reduction

Aside from the anabolic effects, vibration at 45 Hz and 0.3 g also inhibits osteoclast differentiation, reduces actin ring formation, and suppresses several main resorption genes including cathepsin K, MMP-9, and TRAP (Steppe et al., 2020). Kostyshyn et al. (2023) demonstrate in an obese/immobile rat model that WBV at 50 Hz significantly reduces RANKL expression while increasing OPG expression, shifting the OPG/RANKL ratio toward bone formation and away from resorption.

4.4 Mesenchymal stem cell lineage switching

Rajapakse et al. (2021) identify an additional mechanism with particular relevance to ageing bone: LIV significantly decreased vertebral marrow fat fraction in their RCT, suggesting a shift from adipogenic to osteoblastic differentiation of bone marrow mesenchymal stem cells (MSCs).

In ageing and oestrogen-deficient bone marrow, MSCs increasingly differentiate into adipocytes rather than osteoblasts, a process driven in part by PPAR- γ upregulation. Vibration appears to suppress adipogenesis and redirect MSC differentiation toward osteoblastogenesis. Steppe et al. (2020) also confirm this in multiple cell culture models. Sassi (2024), studying osteocyte-cancer cell interactions, further demonstrates that vibration-stimulated osteocytes alter their secretory profiles in ways that change their cellular environment which is consistent with the notion that osteocytes are active regulators of bone marrow biology instead of passive bystanders.

4.5 The LINC complex and cytoskeletal mechanotransduction

Olçum et al. (2016) describe the role of the LINC complex (Linker of Nucleoskeleton and Cytoskeleton) as an internal mechanical amplification mechanism: low-magnitude external vibration is amplified within cells through cytoskeletal remodeling, allowing signals that appear too weak to generate significant bone strain to trigger intracellular signaling cascades. This mechanism explains the apparent paradox that low-magnitude vibration (0.1–0.3 g notably lower than the habitual physical activity loads) can produce measurable osteogenic effects.

5. Limitations and gaps in the literature

5.1 Extreme protocol heterogeneity

As documented throughout this review, the vibration therapy literature is characterised by a high protocol heterogeneity across essentially every parameter: frequency (8–90 Hz), magnitude (0.1–12 g), session duration (1–60 min), session frequency (2/week up to daily), platform type (synchronous vs. side-alternating; standing vs. wearable), posture during vibration (static vs. Exercising, or the angle knee), and total intervention duration (4 weeks to 22 months).

This makes cross-study comparison unreliable and meta-analytic pooling problematic, as Fratini et al. (2016) and Oliveira et al. (2016) demonstrate. Without consensus protocol standards, the field cannot determine optimal parameters or make clear and reliable clinical recommendations.

5.2 DXA insensitivity as a measurement limitation

DXA measures BMD: a two-dimensional projection of a three-dimensional structure; and is relatively insensitive to changes in bone microarchitecture, trabecular connectivity, cortical thickness, and bone stiffness. Multiple studies in this review (Bilek et al., 2024, DadeMatthews et al., 2022, Rajapakse et al., 2021) demonstrate that vibration therapy can produce significant improvements in bone quality metrics detectable by MRI, CT, or BCT while showing no significant DXA changes.

This means the field might be repeatedly underestimating the efficacy of vibration by relying on the wrong



364 measurement tool. Future studies should make more use of pQCT, HR-pQCT, or BCT as primary or co-primary
365 outcomes.

366 **5.3 Paucity of osteopenia-specific studies**

367 Only a minority of the sources reviewed specifically target osteopenic populations. The majority studied
368 osteoporosis or mixed populations throughout the T-score values. This means that most evidence for vibration
369 therapy's effects on osteopenia is extrapolated from adjacent populations. Given that the response to treatment, and
370 the clinical goals differ between osteopenia and osteoporosis (prevention of progression vs. fracture prevention and
371 reversal), further dedicated osteopenia studies are needed.

372 Marini et al. (2021) make this point starkly: their systematic review of combined physical-pharmacological
373 treatment in osteopenia and osteoporosis found only a single eligible RCT in the world literature.

374 **5.4 Underrepresentation of men**

375 Men are profoundly underrepresented across the corpus, comprising a small fraction of study participants in
376 most reviews and being entirely excluded from many trials. Given that men do develop osteopenia and osteoporosis
377 (at lower rates but with potentially higher fracture mortality), and that secondary causes (hypogonadism,
378 corticosteroid use) are common, this represents a significant evidence gap.

379 **5.5 Short intervention durations and follow-up periods**

380 Many studies in the reviewed literature used intervention durations of 12 weeks to 6 months which is
381 potentially insufficient for the bone remodeling cycle which takes usually around 3–6 months per cycle to produce
382 detectable BMD changes.

383 Massini et al. (2025) find that protocols of less than 18 weeks are most probably insufficient. Li et al. (2024)
384 observe that significant BMD effects at 6 months were not sustained at 12 months, though this may reflect a
385 treatment plateau rather than reversal. Long-term follow-up (more than 2 years) and durability of effect data remain
386 scarce.

387 **5.6 Small sample sizes and statistical power**

388 Many individual RCTs lack the necessary evaluation procedures to detect the small BMD effect sizes
389 expected from vibration therapy. Massini et al. (2025) note that low certainty of evidence at the femoral neck and
390 lumbar spine is partly attributable to small sample sizes across individual studies. The largest meta-analyses (de
391 Oliveira et al., 2022, Zhang et al., 2022) obtain partial results through aggregation of data, but the methodological
392 quality of primary studies still remains variable.

393 **5.7 Adverse effects and long-term safety**

394 The short-term safety profile of low-magnitude vibration therapy is well-supported: de Oliveira et al. (2022)
395 report an adverse event rate of only 2.8% across 2,089 participants. Furthermore, no serious adverse events were
396 reported in the 15 systematic reviews included in Yin et al. (2024). However, high-magnitude WBV (≥ 1 g) in
397 osteopenic or osteoporotic individuals is explicitly cautioned against by de Oliveira et al. (2022) due to fracture risk.

398 **6. Clinical implications and recommendations**

399 **6.1 Evidence-based protocol parameters**

400 Based on the data obtained in this review, the following vibration therapy parameters are best supported for
401 osteopenic patients seeking bone density maintenance or modest improvement. It must be noted that exercising



during vibration sessions appears to reduce osteogenic efficacy compared to static standing (Fratini et al., 2016), though combined vibration-exercise programs may better address the functional and neuromuscular goals of osteopenia management. These are presented as a practical reference and should be individualised based on patient characteristics.

Table 2. Relevant vibration therapy parameters

Study	Frequency	Magnitude	Session	Duration	Platform
Rajapakse (2021)	30 Hz	0.3 g	10 min/day	12 months	Standing, feet
Beck / VIBMOR (2022)	30 Hz	0.4 g	10 min/day	9 months	Standing, feet
Qin / VIBE (2019)	30 Hz	0.3 g	10 min/day	90 days	Supine, feet
Tan (2016)	35 Hz	0.25 g	15 min/day	4 weeks	Standing, feet
Bilek / Osteoboost (2024)	20–40 Hz	0.1–0.3 g	30 min/day	12 months	Wearable belt
Dutra (2016)	60 Hz	0.6 g (<1mm)	20 min/day	12 months	Vertical platform
Sen (2020)	30–40 Hz	2–4 mm amp.	Not specified	6 months	WBV platform
He (2022)	8–10 Hz	2 mm amp.	5 min, 2×/wk	24 weeks	WBV platform
Kienberger (2022)	18–20 Hz	2 mm amp.	~6 min, 2×/wk	12 months	Galileo, side-alt.

6.2 Target population and timing

The strongest evidence for vibration therapy effectiveness is in postmenopausal women aged 50–65 which is the population experiencing the highest bone loss rate and greatest potential for BMD modification. The evidence for the >65 age group is more equivocal, and both Marín-Cascales et al. (2018) and Tan et al. (2016) identify diminished osteogenic response after this threshold. However, functional benefits such as strength, balance and the reduction of fall risk are consistently demonstrated across all age groups, making vibration therapy an acceptable intervention in older cohorts even if BMD gains are not the main target.

Patients with lower BMD within the osteopenic range may respond better, given the inverse relationship between baseline BMD and vibration response (Fratini et al., 2016; Rajapakse et al., 2021). Body weight should also be considered: de Oliveira et al. (2022) find that women under 65 kg show greater lumbar spine BMD responses.

6.3 Use of DXA vs. advanced imaging for monitoring

In light of DXA's demonstrated insensitivity to the microstructural benefits of vibration therapy (Bilek et al., 2024, Rajapakse et al., 2021;), clinicians and researchers monitoring patients receiving vibration therapy should consider supplementing annual DXA with bone quality assessments where feasible, including vertebral fracture assessment, FRAX score updates, and, where available, pQCT or CT-based bone strength measures. Absence of DXA improvement does not rule out clinically meaningful bone quality benefits.

6.4 Safety considerations

Low-magnitude vibration therapy (≤ 0.3 – 0.4 g) delivered through the feet via standing platforms or wearable devices has an excellent short-term safety profile across multiple large studies. Key safety considerations include: avoiding high-magnitude protocols (>1 g) in osteopenic and osteoporotic patients due to fracture risk.

On the same note, ensuring appropriate posture during vibration sessions (such as semi-flexed knees preferred over fully extended), screening for contraindications (e.g. recent fractures, implanted hardware, active



448 deep vein thrombosis, and severe inner ear disorders) and using frequencies ≤ 50 Hz in frail or elderly populations,
449 are also important, given that Massini et al.'s (2025) cautions against higher frequencies which increase adverse
450 event risk.

451 **6.5 Priorities for future research**

452 This review identifies the following as important areas for future research in vibration therapy for
453 osteopenia:

- 454 • Dedicated RCTs in osteopenic (not osteoporotic) populations, with sufficient sample size and duration (≥ 12
455 months) to detect BMD effects with adequate power
- 456 • Male-specific trials and sub-group analyses in mixed-sex studies, given the current near-total absence of
457 male data
- 458 • Protocol standardisation studies comparing frequency x magnitude x duration combinations systematically
459 in controlled designs
- 460 • Use of advanced imaging (HR-pQCT, BCT, MRI) as primary or co-primary outcomes alongside DXA
- 461 • Biomarker studies with standardised timing protocols to resolve the apparent disconnect between structural
462 and biochemical markers of bone response
- 463 • Long-term studies (≥ 24 months) examining durability of effect and optimal maintenance protocols after
464 initial benefit is achieved
- 465 • Studies combining targeted axial vibration (wearable devices) with pharmacological agents in osteopenic
466 populations

467 **3. Conclusions**

468 This narrative review, synthesising 40 sources on vibration therapy and bone pathology, supports a
469 relatively optimistic assessment of vibration therapy's role in osteopenia management. The evidence is strongest for
470 three main conclusions:

471 The first one, that low-magnitude vibration therapy (approximately 30 Hz, 0.3 g) applied axially through the
472 lower limbs has the highest-quality evidence for BMD stabilisation and modest improvement in postmenopausal
473 women; The second is that functional benefits such as muscle strength, balance, fall risk reduction are more
474 consistent and robust than BMD effects and are clinically important. The third one is that the OsteoBoost wearable
475 belt, now FDA-cleared specifically for osteopenia, represents a significant clinical advance in targeted axial
476 vibration delivery and suggests a future direction for non-platform vibration therapy.

477 Key limitations that temper these conclusions include the protocol variety across studies, DXA's technical
478 insensitivity to microstructural improvements, the lack of dedicated osteopenia studies, the near-total absence of
479 male-specific evidence, and the short duration of most trials. These limitations mean that the current evidence, while
480 promising, does not yet support a definite clinical recommendation of vibration therapy as a primary treatment of
481 osteopenia

482 The prospects are encouraging. The development of wearable axial vibration devices, the increasing number
483 of meta-analyses on low-magnitude protocols, the growing mechanistic understanding of osteocyte and MSC
484 biology under vibration, and the consistent demonstration of functional benefits across diverse populations all point
485 toward a possible clinically viable modality that requires continued investigation and, in specific clinical contexts,
486 implementation under supervision.

487 **4. References**

- 488 Akbar, A., Zaheer, A., Kharal, M. M., Komel, A., Khan, M. H., Ahsan, A., & Singh, A. K. (2025). Evolving
489 strategies for osteoporosis management in postmenopausal women: From tradition to innovation.
490 *Medicine*, 104(7), e41605. <https://doi.org/10.1097/MD.00000000000041605>
- 491 Beck, B., Rubin, C., Harding, A., et al. (2022). The effect of low-intensity whole-body vibration with or
492 without high-intensity resistance and impact training on risk factors for proximal femur fragility fracture



499 in postmenopausal women with low bone mass: Study protocol for the VIBMOR randomized controlled
500 trial. *Trials*, 23, 15. <https://doi.org/10.1186/s13063-021-05911-4>

501 Bembem, D. (2020). Application of vibration training for enhancing bone strength. In J. Rittweger (Ed.),
502 Manual of vibration exercise and vibration therapy (pp. 19). Springer. https://doi.org/10.1007/978-3-030-43985-9_19

503 Bilek, L. D., Flores, L. E., Waltman, N., Smith, K., Hillstrom, D., Yecies, L., & Jaasma, M. J. (2025).
504 Wearable vibration therapy for low bone density: High adherence and usability scores in a 12-month
505 clinical trial. *Journal of the Endocrine Society*, 9(Supplement_1), bvaf149.544.
506 <https://doi.org/10.1210/jendso/bvaf149.544>

507 Bilek, L. D., Flores, L. E., Waltman, N., Mack, L. R., Smith, K., Kelly, C., Keaveny, T. M., Hillstrom, D.,
508 Griffin, M., Yecies, L., & Jaasma, M. J. (2024). Benefits of targeted vibration for bone strength and bone
509 density in postmenopausal women with osteopenia: A randomized, sham-controlled trial. *JBMR Plus*,
510 ziaef104. <https://doi.org/10.1093/jbmrpl/ziaef104>

511 Chen, W., Li, X., & Chen, C. (2026). Whole-body vibration training and bone mineral density in older adults:
512 An updated systematic review and meta-analysis. *BMC Musculoskeletal Disorders*, 27(1), 149.
513 <https://doi.org/10.1186/s12891-026-09504-7>

514 Chłystek, J., Pietsch, J., Golus, A., Abramczyk, A., & Lakomski, M. (2018). Review of physiotherapeutic
515 methods used in patients with osteoporosis. *Journal of Education, Health and Sport*, 8(9), 1058–1066.

516 Dade Matthews, O. O., Agostinelli, P. J., Neal, F. K., Oladipupo, S. O., Hirschhorn, R. M., Wilson, A. E., &
517 Sefton, J. M. (2022). Systematic review and meta-analyses on the effects of whole-body vibration on
518 bone health. *Complementary Therapies in Medicine*, 65, 102811.
519 <https://doi.org/10.1016/j.ctim.2022.102811>

520 de Oliveira, R. D. J., de Oliveira, R. G., de Oliveira, L. C., Santos-Filho, S. D., Sá-Caputo, D. C., &
521 Bernardo-Filho, M. (2023). Effectiveness of whole-body vibration on bone mineral density in
522 postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
523 *Osteoporosis International*, 34(1), 29–52. <https://doi.org/10.1007/s00198-022-06556-y>

524 Dionello, C. F., Sá-Caputo, D., Pereira, H. V., Sousa-Gonçalves, C. R., Maiworm, A. I., Morel, D. S.,
525 Moreira-Marconi, E., Paineiras-Domingos, L. L., Bembem, D., & Bernardo-Filho, M. (2016). Effects of
526 whole body vibration exercises on bone mineral density of women with postmenopausal osteoporosis
527 without medications: Novel findings and literature review. *Journal of Musculoskeletal and Neuronal*
528 *Interactions*, 16(3), 193–203.

529 Dutra, M. C., de Oliveira, M. L., Marin, R. V., Kleine, H. C. R., Silva, O. L., & Lazaretti-Castro, M. (2016).
530 Whole-body vibration improves neuromuscular parameters and functional capacity in osteopenic
531 postmenopausal women. *Menopause*, 23(8), 870–875. <https://doi.org/10.1097/GME.0000000000000644>

532 Ebid, A., El-Boshy, M., El-Shamy, S., Thabet, A., Abedalla, M., & Ali, T. (2021). Long-term effect of full-
533 body pulsed electromagnetic field and exercise protocol in the treatment of men with osteopenia or
534 osteoporosis: A randomized placebo-controlled trial. *F1000Research*, 10, 649.
535 <https://doi.org/10.12688/f1000research.54519.3>

536 Fillit, H. M., Rockwood, K., & Young, J. B. (Eds.). (2016). *Brocklehurst's textbook of geriatric medicine and*
537 *gerontology* (8th ed.). Saunders/Elsevier.

538 Flores, J., Metchkoff, T., Chen, E., Auslander, A., Rocha-Rangel, J., & Liang, M. (2016). Effect of four
539 weeks whole-body vibration training on bone mineral density, and bending strength in young adults.

540 Fratini, A., Bonci, T., & Bull, A. M. (2016). Whole body vibration treatments in postmenopausal women can
541 improve bone mineral density: Results of a stimulus focussed meta-analysis. *PLOS ONE*, 11(12),
542 e0166774. <https://doi.org/10.1371/journal.pone.0166774>

543 Guedes De Aguiar, E. O., Moreira Marconi, E., Monteiro-Oliveira, B. B., Gomes-Santos, A. C., Coelho
544 Oliveira, A. C., Paineiras-Domingos, L. L., Sá-Caputo, D. C., & Bernardo Filho, M. (2023). Whole-body
545 vibration exercise improves the functionality in postmenopausal women: A systematic review. *Iranian*
546 *Journal of Public Health*, 52(3), 476–487. <https://doi.org/10.18502/ijph.v52i3.12131>

547 Harvard Health Publishing. (2011, November 17). Whole-body vibration doesn't slow bone loss. Harvard
548 Medical School. <https://www.health.harvard.edu/blog/whole-body-vibration-doesnt-slow-bone-loss->
549



201111173820

- 550 He, Z., Zheng, J., Liu, S., et al. (2022). The effect of whole-body vibration in osteopenic patients after total
551 knee arthroplasty: A randomized controlled trial. *Aging Clinical and Experimental Research*, 34, 1381–
552 1390. <https://doi.org/10.1007/s40520-021-02043-2>
- 553 Kienberger, Y., Sassmann, R., Rieder, F., et al. (2022). Effects of whole body vibration in postmenopausal
554 osteopenic women on bone mineral density, muscle strength, postural control and quality of life: The T-
555 bone randomized trial. *European Journal of Applied Physiology*, 122, 2331–2342.
556 <https://doi.org/10.1007/s00421-022-05010-5>
- 557 Kostyshyn, N. M., Muszynski, S., Tomaszewska, E., Tomczyk-Warunek, A., Puzio, I., & Dobrowolski, P.
558 (2023). Effect of mechanical stimuli and zoledronic acid on the femoral bone morphology in rats with
559 obesity and limited mobility. *Journal of Clinical Medicine*, 12(1), 43.
560 <https://doi.org/10.3390/jcm12010043>
- 561 Li, Q., Liang, L., Gao, C., & Zong, B. (2024). Therapeutic effects of whole-body vibration on
562 postmenopausal women with osteoporosis: A systematic review and meta-analysis. *Brazilian Journal of*
563 *Medical and Biological Research*, 57, e13996. <https://doi.org/10.1590/1414-431X2024e13996>
- 564 Luo, X., Zhang, J., Zhang, C., He, C., & Wang, P. (2017). The effect of whole-body vibration therapy on
565 bone metabolism, motor function, and anthropometric parameters in women with postmenopausal
566 osteoporosis. *Disability and Rehabilitation*, 39(22), 2315–2323.
567 <https://doi.org/10.1080/09638288.2016.1226417>
- 568 Ma, C., Liu, A., Sun, M., et al. (2016). Effect of whole-body vibration on reduction of bone loss and fall
569 prevention in postmenopausal women: A meta-analysis and systematic review. *Journal of Orthopaedic*
570 *Surgery and Research*, 11, 24. <https://doi.org/10.1186/s13018-016-0357-2>
- 571 Marín-Cascales, E., Alcaraz, P. E., Ramos-Campo, D. J., Martínez-Rodríguez, A., Chung, L. H., & Rubio-
572 Arias, J. Á. (2018). Whole-body vibration training and bone health in postmenopausal women: A
573 systematic review and meta-analysis. *Medicine*, 97(34), e11918.
574 <https://doi.org/10.1097/MD.00000000000011918>
- 575 Marini, S., Barone, G., Masini, A., Dallolio, L., Bragonzoni, L., Longobucco, Y., & Maffei, F. (2021).
576 Current lack of evidence for an effect of physical activity intervention combined with pharmacological
577 treatment on bone turnover biomarkers in people with osteopenia and osteoporosis: A systematic review.
578 *Journal of Clinical Medicine*, 10(15), 3442. <https://doi.org/10.3390/jcm10153442>
- 579 Massini, D. A., Almeida, T. A. F., Macedo, A. G., Peres, A. B., Hernández-Beltrán, V., Gamonales, J. M.,
580 Espada, M. C., Neiva, C. M., & Pessôa Filho, D. M. (2025). Effect of whole-body vibration training on
581 bone mineral density in older adults: A systematic review and meta-analysis. *PeerJ*, 13, e19230.
582 <https://doi.org/10.7717/peerj.19230>
- 583 National Library of Medicine. (n.d.). PubMed Central. <https://pubmed.ncbi.nlm.nih.gov/articles/PMC11396361/>
- 584 Oliveira, L. C., Oliveira, R. G., & Pires-Oliveira, D. A. A. (2016). Effects of whole body vibration on bone
585 mineral density in postmenopausal women: A systematic review and meta-analysis. *Osteoporosis*
586 *International*, 27, 2913–2933. <https://doi.org/10.1007/s00198-016-3618-3>
- 587 Physiopedia. (n.d.). Vibration therapy. https://www.physio-pedia.com/Vibration_Therapy
- 588 Qin, Y. X., Xia, Y., Muir, J., Lin, W., & Rubin, C. T. (2018). Quantitative ultrasound imaging monitoring
589 progressive disuse osteopenia and mechanical stimulation mitigation in calcaneus region through a 90-
590 day bed rest human study. *Journal of Orthopaedic Translation*, 18, 48–58.
591 <https://doi.org/10.1016/j.jot.2018.11.004>
- 592 Rajapakse, C. S., Johncola, A. J., Batzdorf, A. S., Jones, B. C., Al Mukaddam, M., Sexton, K., Shults, J.,
593 Leonard, M. B., Snyder, P. J., & Wehrli, F. W. (2021). Effect of low-intensity vibration on bone strength,
594 microstructure, and adiposity in pre-osteoporotic postmenopausal women: A randomized placebo-
595 controlled trial. *Journal of Bone and Mineral Research*, 36(4), 673–684.
596 <https://doi.org/10.1002/jbmr.4229>
- 597 Royal Osteoporosis Society. (n.d.). Vibration therapy. <https://theros.org.uk/information-and-support/osteoporosis/living-with-osteoporosis/exercise-and-physical-activity-for-osteoporosis/vibration-therapy/>
- 600



- 601 Runge, W. O., Ruppert, D. S., Marcellin-Little, D. J., Dahners, L. E., Harrysson, O., & Weinhold, P. S.
602 (2018). Bone changes after short-term whole body vibration are confined to cancellous bone. *Journal of*
603 *Musculoskeletal and Neuronal Interactions*, 18(4), 485–492.
- 604 Sassi, A. (2024). Investigating the effects of low-magnitude high-frequency vibration on prostate cancer
605 growth and bone metastasis [Master's thesis, University of Toronto]. ProQuest.
606 <https://www.proquest.com/openview/93697d7f30b309bac37351a04ad5c9e6/1>
- 607 Sen, E. I., Esmailzadeh, S., & Eskiyurt, N. (2020). Effects of whole-body vibration and high impact
608 exercises on the bone metabolism and functional mobility in postmenopausal women. *Journal of Bone*
609 *and Mineral Metabolism*, 38(3), 392–404. <https://doi.org/10.1007/s00774-019-01072-2>
- 610 Singh, A., & Varma, A. R. (2023). Whole-body vibration therapy as a modality for treatment of senile and
611 postmenopausal osteoporosis: A review article. *Cureus*, 15(1), e33690.
612 <https://doi.org/10.7759/cureus.33690>
- 613 Steppe, L., Liedert, A., Ignatius, A., & Haffner-Luntzer, M. (2020). Influence of low-magnitude high-
614 frequency vibration on bone cells and bone regeneration. *Frontiers in Bioengineering and Biotechnology*,
615 8, 595139. <https://doi.org/10.3389/fbioe.2020.595139>
- 616 Swe, M., Benjamin, B., Tun, A. A., & Sugathan, S. (2016). Role of the whole body vibration machine in the
617 prevention and management of osteoporosis in old age: A systematic review. *Malaysian Journal of*
618 *Medical Sciences*, 23(5), 8–16. <https://doi.org/10.21315/mjms2016.23.5.2>
- 619 Tan, L., Li, Y. H., Dong, X., Zhao, B., & Zhu, D. (2016). Effect of 4-week whole body vibration on distal
620 radius density. *Chinese Medical Sciences Journal*, 31(2), 95–99. [https://doi.org/10.1016/s1001-](https://doi.org/10.1016/s1001-9294(16)30032-3)
621 [9294\(16\)30032-3](https://doi.org/10.1016/s1001-9294(16)30032-3)
- 622 Tomasevic-Todorovic, S., Savic, D., Nikolic, S., Todorovic, M., & Spasojevic, T. (2024). Osteoporotic
623 vertebral fractures: From diagnosis to rehabilitation. *Acta Medica Medianae*, 63, 69–75.
624 <https://doi.org/10.5633/amm.2024.0209>
- 625 Uzan, M. O., Baskan, Ö., Karadas, Ö., & Özçivici, E. (2016). Application of low intensity mechanical
626 vibrations for bone tissue maintenance and regeneration. *Turkish Journal of Biology*, 40(2), 300–307.
627 <https://doi.org/10.3906/biy-1506-76>
- 628 Varacallo, M. A., Seaman, T. J., Jandu, J. S., et al. (2026). Osteopenia. In *StatPearls*. StatPearls Publishing.
629 <https://www.ncbi.nlm.nih.gov/books/NBK499878/>
- 630 Yin, S., Liu, Y., Zhong, Y., & Zhu, F. (2024). Effects of whole-body vibration on bone mineral density in
631 postmenopausal women: An overview of systematic reviews. *BMC Women's Health*, 24(1), 444.
632 <https://doi.org/10.1186/s12905-024-03290-x>
- 633 Zhang, S., Huang, X., Zhao, X., Li, B., Cai, Y., Liang, X., & Wan, Q. (2022). Effect of exercise on bone
634 mineral density among patients with osteoporosis and osteopenia: A systematic review and network meta-
635 analysis. *Journal of Clinical Nursing*, 31, 2100–2111. <https://doi.org/10.1111/jocn.161>